Atara reports Q3 2026 results as tab-cel BLA resubmission moves toward March 2027 FDA decisionNov 10Quarterly updateAtara Biotherapeutics, Inc.
Addex names Jean-Philippe Rocher head of pharmaceutical development as Kalinichev departsOct 2PeopleAddex Therapeutics Ltd.